Barclays PLC Grows Stock Position in Precigen, Inc. (NASDAQ:PGEN)

Barclays PLC grew its position in shares of Precigen, Inc. (NASDAQ:PGEN) by 190.4% during the third quarter, Holdings Channel reports. The institutional investor owned 189,353 shares of the biotechnology company’s stock after purchasing an additional 124,141 shares during the quarter. Barclays PLC’s holdings in Precigen were worth $179,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp raised its stake in Precigen by 4.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 421,788 shares of the biotechnology company’s stock valued at $666,000 after acquiring an additional 19,301 shares during the period. ClariVest Asset Management LLC raised its position in shares of Precigen by 2.9% in the second quarter. ClariVest Asset Management LLC now owns 492,152 shares of the biotechnology company’s stock valued at $778,000 after purchasing an additional 13,752 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Precigen by 12.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock valued at $1,869,000 after buying an additional 130,500 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Precigen by 56.7% in the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after buying an additional 18,097 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in Precigen by 40.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 16,486 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Precigen in a research note on Friday, November 15th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.00.

Precigen Stock Up 3.9 %

NASDAQ PGEN opened at $1.32 on Wednesday. Precigen, Inc. has a twelve month low of $0.65 and a twelve month high of $1.93. The stock’s 50-day simple moving average is $0.87 and its two-hundred day simple moving average is $1.09. The company has a market capitalization of $386.59 million, a price-to-earnings ratio of -2.40 and a beta of 1.65.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.